ClinicalTrials.gg
WithdrawnNCT03749733Updated Jul 15, 2019

Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

A Phase 1 interventional study of Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product) and Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product) in Bioequivalence, sponsored by Grünenthal GmbH. Withdrawn at 1 site in Mexico. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Basic science

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

This study will investigate the bioavailability in fasting post-menopausal women of 2 film-coated tablet formulations containing 1.5 milligrams (mg) of estradiol and 2.5 mg of nomegestrol acetate.

The study will be performed at a single site. Participants will take a single oral dose of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 21 days between each study period.

Read the detailed description

The primary objective of the study is to investigate the relative bioavailability of estradiol and nomegestrol of 2 film-coated tablet formulations with estradiol 1.5 mg and nomegestrol acetate 2.5 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

  1. Test Product: new product manufactured by Laboratorios Andrómaco S.A.
  2. Reference Product: Stezza [Trademark], product of Merck Sharp \& Dohme Farmacêutica Ltda.

The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to 72 hours (AUC0-72), and maximum plasma concentration (Cmax) for total estradiol/estrone and nomegestrol will be determined.

Participants will be confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. Three blood samples will be taken before the film-coated tablet is administered (at pre-dose: -1.0, -0.5, and 0 h) and 16 samples up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 36 h, 48 h, and 72 h post-dose.

The washout period between the two study periods will be at least 21 days.

The samples from each participant will be analyzed with 2 methods of high-performance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total estradiol/estrone and nomegestrol in plasma with citrate phosphate dextrose anticoagulant. The blood samples taken at pre-dose will be taken to establish the baseline concentrations of total estrone and estradiol. The baseline-corrected and uncorrected AUCs and Cmax will be calculated.

The safety objective is to evaluate the tolerability of both formulations in post-menopausal women by collecting adverse events.

02

Conditions studied

  • Bioequivalence

Keywords

  • Bioequivalence
  • Estradiol
  • Nomegestrol acetate
03

In context

Lead sponsor

Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Participation will be voluntary and according to the guidelines proposed by the Health General Law (Mexico), and will be obtained according to the previously mentioned law. In addition, the study will be conducted according to the ethical principles that have their origin in the Declaration of Helsinki, the current Brazilian laws, and Good Clinical Practice.

B. Only women aged between 40 years and 65 years who meet any of the following criteria:

  1. 12 months of spontaneous amenorrhea.
  2. 6 months of spontaneous amenorrhea with follicle-stimulating hormone levels above 40 international units per liter and below 20 nanograms per liter estradiol.
  3. Bilateral oophorectomy with or without hysterectomy.

C. The must be between 18.5 and 29.99 kilograms per square meter according to the Quetelet index.

D. Participants must be healthy determined by the results of a complete clinical history recorded by the clinical site physicians and the results of the laboratory examinations done by a certified clinical laboratory.

E. Participants with pre-existing illnesses must be controlled with stable doses of medication for a period of at least 3 months.

F. Non-smoker and/or not having used nicotine or nicotine-containing products (e.g., nicotine plasters) within 3 months prior to the beginning of the study.

G. The allowed limits of variation within normal in the screening visit will be: systolic blood pressure (sitting) below 120 mmHg, diastolic blood pressure below 80 mmHg, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute according to the current standard operating procedure. Vital signs will be measured after 10 minutes of resting in a sitting position.

H. Laboratory and other examinations to be conducted for the inclusion of participants will be:

  1. Complete blood count: leukocytes, erythrocytes, , hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, , neutrophils, lymphocytes, monocytes, eosinophils, basophils.
  2. Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL), cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin/globulin ratio, total , direct bilirubin, indirect bilirubin, , alanine aminotransferase, total alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase, iron, calcium, sodium, potassium, and chloride.
  3. Urinalysis: Physical examination (color, appearance, density); chemical examination (pH, leukocytes, nitrite, protein, glucose, ketones, bilirubin, urobilinogen, hemoglobin); microscopic examination (leukocytes, erythrocytes, dysmorphic erythrocytes, casts, crystals, squamous epithelial cells, tubular renal cells, mucus, bacteria and yeasts).
  4. screening (Antibody to hepatitis B core antigen [Anti-HBc], antibody to hepatitis B surface antigen [HBs-Ab], antibody to hepatitis B surface antigen [Anti-HBs]) and antibodies.
  5. test: Antibodies to the human immunodeficiency virus (Anti-HIV 1 and 2).
  6. Venereal disease research laboratory test (VDRL).
  7. Urine drugs of abuse test at the screening visit and on Day 0 (approximately 12 hours prior to the administration of the investigational medicinal product [IMP] on the previous day) on both study periods.
  8. Alcohol breath test on Day 0 (prior to the administration of the investigational medicinal product on the previous day) on both study periods.
  9. 12-lead which will be performed after resting for 10 minutes in a sitting position.

In addition, each participant will undergo the following examinations:

  1. Complete gynecological profile:

    • Follicle-stimulating hormone (FSH).
    • Luteinizing hormone (LH).
    • Serum estradiol.
    • Serum progesterone.
    • Serum prolactin.
  2. Bilateral mammography (with Breast Imaging Reporting and Data System [BI-RADS] 1 or 2 results).
  3. Transvaginal ultrasound (without findings).
  4. Pap smear (without clinically significant findings).

Exclusion criteria

Exclusion Criteria:

A. Participants with a history of the following diseases: cardiovascular (myocardial infarction, not-controlled hypertension, thromboembolic arterial or venous diseases), renal (kidney failure), hepatic (hepatitis, jaundice), muscular, metabolic, gastrointestinal, neurologic (cerebrovascular disease), psychiatric (depression) endocrinological (not-controlled diabetes mellitus), hematopoietic, respiratory or other organic abnormalities that are not appropriately controlled and that require a pharmacological treatment that could result in a drug interaction with the study medication. Women who have had muscular trauma within 21 days previous to the study will also be excluded.

B. History of major surgeries (cranial surgery, thorax, abdomen or extensive surgeries in extremity requiring the use of general or regional anesthesia and/or respiratory support) within 3 months previous to the study.

C. Participants with a history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer.

D. History of lactose intolerance.

E. Participants who have been exposed to medications known to be hepatic enzyme inducers or inhibitors within 72 hours previous to the start of the study.

F. Participants who have taken any type of vitamin supplements (with or without prescription) or herbal remedies within 30 days (or 7 half-lives) previous to the start of the study.

G. Participants undergoing hormone replacement therapy or taking thyroid hormones.

H. Participants with uterine bleeding.

I. Participants with endometrial thickness equal to or greater than 7 mm as determined in the transvaginal ultrasound.

J. Participants who have been hospitalized for any reason within 6 months prior to study start.

K. Participants who have taken medicinal products from other investigations within 180 days (i.e., 6 months) prior to study start.

L. Participants with a history of allergy or to the study medication (estradiol/nomegestrol), any other medication, food, or substance.

M. Participants who have consumed alcohol, carbonated beverages, or beverages that contain methylxanthines (coffee, tea, cocoa, chocolate, mate, cola, etc.), grapefruit juice, or charbroiled foods within 12 hours prior to the start of the hospitalization period.

N. Participants with any of the following results for : acute infection, chronic infection, or unclear result based on the interpretation of results of the hepatitis B virus serology (CDC Interpretation of Hepatitis B Serologic Test Results).

O. Participants who have donated or lost more than 450 milliliters of blood within 90 days prior to study start.

P. Participants with a history of dependence/abuse of alcohol or psychoactive substances.

Q. Participants requiring a special diet for any reason e.g., vegetarian.

R. Participants unable to understand the nature, objectives, and possible consequences of the study.

S. Evidence of the participant's uncooperativeness during the conduct of the study (unable follow the instructions and requirements of the study personnel).

T. Positive results for drugs of abuse or alcohol breath tests.

U. Participants who are not registered in the Comisión Federal para la Protección contra Riesgos Sanitarios [COFEPRIS]) webpage.

V. Relationship of subordination between the participants and the investigators.

W. Sponsor or clinical site employees.

Discontinuation criteria:

A. Safety and well-being of the participant.

B. Lack of adherence to the procedures and therefore non-compliance with the protocol.

C. Medical reasons (serious adverse events), adverse reactions to the study medication classified as severe.

D. Uncooperative attitude during the conduct of the study (unable follow the instructions and requirements of the study personnel).

E. Recurring or intercurrent disease (not controlled).

F. Withdrawal of consent to participate in the study.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Test Product

    Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg. The tablet will be taken with water and in a fasting condition.

    Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)

  • Active comparator
    Reference Product

    Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg. The tablet will be taken with water and in a fasting condition.

    Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)

Interventions

  • DrugEstradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)

    Drug page: Estradiol

    Marketed Drug

    Also known as: Stezza (Trade Mark)

  • DrugEstradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)

    Drug page: Estradiol

    Investigational Medicinal Product

06

What researchers measure

Primary outcomes

  1. Total estrone (corrected): area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The samples taken at pre-dose will be taken to establish the baseline concentration of total estrone. The baseline-corrected AUC0-t will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  2. Total estradiol (corrected): area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The samples taken at pre-dose will be taken to establish the baseline concentration of total estradiol. The baseline-corrected AUC0-t will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  3. Total nomegestrol: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The samples taken at pre-dose will be taken to establish the baseline concentration of total nomegestrol. The AUC0-72 will be calculated.

    Time frame: From tablet intake and up to 72 hours after tablet intake

  4. Total estrone (corrected): Maximum plasma concentration (Cmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The baseline-corrected Cmax of estrone will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  5. Total estradiol (corrected): Maximum plasma concentration (Cmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The baseline-corrected Cmax of estradiol will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  6. Total nomegestrol: Maximum plasma concentration (Cmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The achieved Cmax of nomegestrol will be calculated.

    Time frame: From tablet intake up to 72 hours after tablet intake

Secondary outcomes

  1. Total estrone: Time to achieve maximum plasma concentration (tmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The tmax of estrone will be calculated.

    Time frame: From tablet intake up to 72 hours after tablet intake

  2. Total estradiol: Time to achieve maximum plasma concentration (tmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The tmax of estradiol will be calculated.

    Time frame: From tablet intake up to 72 hours after tablet intake

  3. Total nomegestrol: Time to achieve maximum plasma concentration (tmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The tmax of nomegestrol will be calculated.

    Time frame: From tablet intake up to 72 hours after tablet intake

  4. Total estrone (uncorrected): area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The samples taken at pre-dose will be taken to establish the baseline concentration of total estrone. The AUC0-t will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  5. Total estradiol (uncorrected): area under the plasma concentration-time curve from 0 to time t (AUC0-t)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The samples taken at pre-dose will be taken to establish the baseline concentration of total estrone. The AUC0-t will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  6. Total estrone (uncorrected): Maximum plasma concentration (Cmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The achieved Cmax of estrone will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

  7. Total estradiol (uncorrected): Maximum plasma concentration (Cmax)

    Three blood samples will be taken before the medication is administered and 19 samples up to 72 hours after the administration in each period. The achieved Cmax of estradiol will be calculated.

    Time frame: Blood samples drawn at baseline (up to 1 hour before tablet intake) and up to 72 hours after tablet intake

07

Study locations

1 site
  • Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V.
    Mexico City, C.P. 14610, Mexico
08

References and documents

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Web Site (see URL below for details)

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · www.grunenthal.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2019; primary completion for Dec 2019, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 21, 2018
StartEst.
Oct 2019
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03749733
Lead sponsor
Grünenthal GmbH
Collaborators
Grünenthal, S.A.
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Oct 2019 (estimated)
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jul 15, 2019

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion